Literature DB >> 29105198

BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity.

Nozomi Nakajima1, Sumihito Nobusawa1, Satoshi Nakata1,2, Mitsutoshi Nakada3, Tatsuya Yamazaki1, Nozomi Matsumura1, Kenichi Harada4, Hadzki Matsuda5, Nobuaki Funata6, Shoichi Nagai7, Hideo Nakamura8, Atsushi Sasaki9, Jiro Akimoto10, Junko Hirato11, Hideaki Yokoo1.   

Abstract

Epithelioid glioblastoma (E-GBM) is a rare aggressive variant of IDH-wildtype glioblastoma newly recognized in the 2016 World Health Organization classification, composed predominantly of monotonous, patternless sheets of round cells with laterally positioned nuclei and plump eosinophilic cytoplasm. Approximately 50% of E-GBM harbor BRAF V600E, which is much less frequently found in other types of glioblastomas. Most E-GBM are recognized as primary/de novo lesions; however, several E-GBM with co- or pre-existing lower-grade lesions have been reported. To better understand associations between E-GBM and the lower-grade lesions, we undertook a histological and molecular analysis of 14 E-GBM, 10 of which exhibited lower-grade glioma-like components (8 E-GBM with co-existing diffuse glioma-like components, 1 E-GBM with a co-existing PXA-like component and 1 E-GBM with a pre-existing PXA). Molecular results demonstrated that the prevalence of BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions in E-GBM were 13/14 (93%), 10/14 (71%) and 11/14 (79%), respectively, and concurrent BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions were observed in 7/14 (50%) of E-GBM. These alterations were also frequently seen in the lower-grade lesions irrespective of the histology. Genetic analysis including array comparative genomic hybridization performed for 5 E-GBM with co- and pre-existing lower-grade components revealed that all molecular changes found in the lower-grade components were also observed in the E-GBM components, and additional changes were detected in the E-GBM components. In conclusion, E-GBM frequently exhibit BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions and these alterations tend to coexist in E-GBM. Taken together with the facts that only one PXA preceded E-GBM among these lower-grade lesions, and that co-occurrence of BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions have been reported to be rare in conventional lower-grade diffuse gliomas, the diffuse glioma-like components may be distinct infiltrative components of E-GBM, reflecting intratumoral heterogeneity.
© 2017 International Society of Neuropathology.

Entities:  

Keywords:  zzm321990BRAFzzm321990; zzm321990CDKN2A/Bzzm321990; zzm321990TERTzzm321990; diffuse astrocytoma; epithelioid glioblastoma

Mesh:

Substances:

Year:  2017        PMID: 29105198     DOI: 10.1111/bpa.12572

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  20 in total

1.  The genetic landscape of anaplastic pleomorphic xanthoastrocytoma.

Authors:  Joanna J Phillips; Henry Gong; Katharine Chen; Nancy M Joseph; Jessica van Ziffle; Boris C Bastian; James P Grenert; Cassie N Kline; Sabine Mueller; Anuradha Banerjee; Theodore Nicolaides; Nalin Gupta; Mitchel S Berger; Han S Lee; Melike Pekmezci; Tarik Tihan; Andrew W Bollen; Arie Perry; Joseph T C Shieh; David A Solomon
Journal:  Brain Pathol       Date:  2018-11-06       Impact factor: 6.508

2.  Clinicopathological characteristics and treatment outcomes of epithelioid glioblastoma.

Authors:  Kaijun Sun; Xingwang Zhou; Tengfei Li; Mingrong Zuo; Junhong Li; Yanhui Liu
Journal:  Neurosurg Rev       Date:  2021-02-17       Impact factor: 3.042

Review 3.  The evolution of pleomorphic xanthoastrocytoma: from genesis to molecular alterations and mimics.

Authors:  Swati Mahajan; Iman Dandapath; Ajay Garg; Mehar C Sharma; Vaishali Suri; Chitra Sarkar
Journal:  Lab Invest       Date:  2022-01-14       Impact factor: 5.662

4.  Clinical and radiological findings of glioblastomas harboring a BRAF V600E mutation.

Authors:  Yukitomo Ishi; Shigeru Yamaguchi; Michinari Okamoto; Ryosuke Sawaya; Shogo Endo; Hiroaki Motegi; Shunsuke Terasaka; Zen-Ichi Tanei; Kanako C Hatanaka; Shinya Tanaka; Miki Fujimura
Journal:  Brain Tumor Pathol       Date:  2022-04-01       Impact factor: 3.298

5.  Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas.

Authors:  Daniel J Brat; Kenneth Aldape; Julia A Bridge; Peter Canoll; Howard Colman; Meera R Hameed; Brent T Harris; Eyas M Hattab; Jason T Huse; Robert B Jenkins; Dolores H Lopez-Terrada; William C McDonald; Fausto J Rodriguez; Lesley H Souter; Carol Colasacco; Nicole E Thomas; Michelle Hawks Yount; Martin J van den Bent; Arie Perry
Journal:  Arch Pathol Lab Med       Date:  2022-05-01       Impact factor: 5.686

6.  Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy.

Authors:  Yu Kanemaru; Manabu Natsumeda; Masayasu Okada; Rie Saito; Daiki Kobayashi; Takeyoshi Eda; Jun Watanabe; Shoji Saito; Yoshihiro Tsukamoto; Makoto Oishi; Hirotake Saito; Masayuki Nagahashi; Takahiro Sasaki; Rintaro Hashizume; Hidefumi Aoyama; Toshifumi Wakai; Akiyoshi Kakita; Yukihiko Fujii
Journal:  Acta Neuropathol Commun       Date:  2019-07-25       Impact factor: 7.801

7.  Clinicopathological, Immunohistochemical and Molecular Genetic Study on Epithelioid Glioblastoma: A Series of Fifteen Cases with Literature Review.

Authors:  Ying Zeng; Xiangfeng Zhu; Yali Wang; Bo Liu; Xin Yang; Qiushi Wang; Juan Du; Yu Ma; Li Lin; Ping Fu; Hualiang Xiao; Qiao-Nan Guo
Journal:  Onco Targets Ther       Date:  2020-05-08       Impact factor: 4.147

8.  Less-invasive diagnosis of disseminated epithelioid glioblastoma harboring BRAF V600E mutation by cerebrospinal fluid analysis-A case report.

Authors:  Manabu Natsumeda; Yu Kanemaru; Yukie Kawaguchi; Hajime Umezu; Akiyoshi Kakita; Yukihiko Fujii
Journal:  Clin Case Rep       Date:  2021-07-16

9.  TERT Promoter Mutation Analysis for Blood-Based Diagnosis and Monitoring of Gliomas.

Authors:  Leonora Balaj; Bob S Carter; Koushik Muralidharan; Anudeep Yekula; Julia L Small; Zachary S Rosh; Keiko M Kang; Lan Wang; Spencer Lau; Hui Zhang; Hakho Lee; Chetan Bettegowda; Michael R Chicoine; Steven N Kalkanis; Ganesh M Shankar; Brian V Nahed; William T Curry; Pamela S Jones; Daniel P Cahill
Journal:  Clin Cancer Res       Date:  2020-10-13       Impact factor: 13.801

10.  Coexistence of TERT Promoter Mutations and the BRAF V600E Alteration and Its Impact on Histopathological Features of Papillary Thyroid Carcinoma in a Selected Series of Polish Patients.

Authors:  Dagmara Rusinek; Aleksandra Pfeifer; Jolanta Krajewska; Malgorzata Oczko-Wojciechowska; Daria Handkiewicz-Junak; Agnieszka Pawlaczek; Jadwiga Zebracka-Gala; Malgorzata Kowalska; Renata Cyplinska; Ewa Zembala-Nozynska; Mykola Chekan; Ewa Chmielik; Aleksandra Kropinska; Roman Lamch; Beata Jurecka-Lubieniecka; Barbara Jarzab; Agnieszka Czarniecka
Journal:  Int J Mol Sci       Date:  2018-09-06       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.